Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer

Clinical trial NCT04736199 · COMPLETED

Trial details

NCT number: NCT04736199
Sponsor: Bayer
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Prostatic Neoplasms

Start date: 2021-02-23
Primary completion: 2024-06-07
Enrollment: 669

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.